Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Wine's secret signals: study probes how a glass affects aging cells

NCT ID NCT07361887

Knowledge-focused Sponsor: University of Seville Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how moderate wine consumption changes tiny particles called extracellular vesicles, which help cells communicate. Eight healthy adults aged 35-65 will drink red wine, white wine, or water, and researchers will analyze their blood for changes in these particles. The goal is to better understand how moderate wine intake might influence heart and brain health as we age.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Wine (red or white)
What this could lead to
If successful, this could reveal how moderate wine drinking may support healthy aging by improving communication between cells.
What could go wrong
This is a very small, early-stage study with only 8 participants, so results may not apply to everyone. It looks at short-term effects, not long-term health outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 8 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

35 to 36 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Healthy adult men and women aged 35 to 65 years. * Body Mass Index (BMI) between 18.5 and 29.9 kg/m². * Non-smokers or ex-smokers for at least 12 months. * Moderate alcohol consumers, defined as ≤2 units/day for men and ≤1 unit/day for women. * Normal fasting glucose and lipid profile at screening. * Willing and able to refrain from alcohol, polyphenol-rich foods, and intense exercise for 48 hours before each study visit. * Able to understand the study procedures and provide written informed consent. Exclusion Criteria * History or clinical evidence of cardiovascular, hepatic, renal, thyroid, gastrointestinal, or metabolic diseases (including diabetes, dyslipidemia, or hypertension). * Use of medications or supplements known to affect glucose, lipid, or inflammatory metabolism (e.g., statins, corticosteroids, anti-inflammatory drugs). * Pregnancy or breastfeeding. * Recent blood donation (within the last 3 months) or planned blood donation during the study period. * Major weight change (\>5% of body weight) within the last 3 months. * Participation in another clinical or biomedical study within the previous 3 months. * Known allergy or intolerance to wine, alcohol, or its components (e.g., sulfites). * History of alcohol abuse or inability to abstain from alcohol outside the study context. * Reluctance to receive information about incidental health findings arising from the study. * Any condition judged by the investigators to limit compliance or increase study risk (e.g., psychiatric disorders, inability to adhere to fasting requirements).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer's disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

abdominal obesity-metabolic syndrome Alzheimer disease atherosclerotic cardiovascular disease Inflammation inflammatory disease metabolic disease metabolic syndrome X Nerve Degeneration neurodegenerative disease Obesity obesity disorder vascular disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer's disease Atherosclerosis cardiovascular disease Inflammation Metabolic disorders Metabolic syndrome Neurodegeneration Neurodegenerative disease Obesity

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Av. de Sánchez Pizjuán, s/n, 41009 Sevilla Facultad de Medicina . Universidad de Sevilla

    RECRUITING

    Seville, Sevilla, 41009, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.